Business
Benitec is a clinical-stage biotechnology company developing genetic medicines using DNA-directed RNA interference, or ddRNAi.
Benitec is a clinical-stage gene-medicine company with no standard revenue row, a larger FY2025 loss, cash burn, and a large insider purchase signal.
The read at a glance✓ Audited against SEC data
- Business mix — ddRNAi gene medicinesNote
- Revenue — No standard revenue rowWatch
- FCF — -$23.6MWatch
- Loss — Net loss $37.9MWatch
- Equity — $97.3M, +105.9%OK
- Insiders — $10.5M purchases / 0 salesOK
- Accounting — Altman FY2021 distress; no current Beneish/EQWatch
Where the revenue comes from
Fiscal 2023, as Benitec Biopharma Inc. reports it. History and quarterly detail are in the app.
- License$75K
Leadership changes
From Benitec Biopharma Inc.'s own filings, the day they're filed.
- David Friedman · director · appointmenteff. 2026-05-22
- Sharon Mates · director · appointmenteff. 2025-11-03
- Sophie Mukadam · Chief Operating Officer · appointmenteff. 2025-01-01
Latest filings
- 8-K · Company announcement2026-05-29
- 10-Q · Quarterly report2026-05-14
- 8-K · Company announcement2026-05-14
- 10-Q · Quarterly report2026-02-12
- 8-K · Company announcement2026-02-12
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Benitec Biopharma Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.